CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 72 enrolled
Drug / intervention
etonogestrel implantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03282799
NCT03282799Phase 2Completed

Pharmacokinetic and Pharmacodynamic Evaluation of Etonogestrel Dose Escalation With Efavirenz-based Antiretroviral Therapy in HIV-infected Ugandan

Catherine Anne Chappell·interventional·Posted Sep 14, 2017·Updated Sep 5, 2024

In Brief

A Phase 2 clinical trial evaluating etonogestrel implant for HIV/AIDS and Contraception. Completed, enrolled 72 participants across 1 site.

Detailed Summary

This study will evaluate the frequency of ovulation and cervical mucus quality of HIV-infected Ugandan women on efavirenz-based antiretroviral therapy using either a single etonogestrel implant or two etonogestrel implants for at least one year.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUganda

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 14, 2017
Enrollment StartFeb 19, 2019
Primary CompletionDec 22, 2020
Study CompletionOct 25, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.8 years ago

Interventions

etonogestrel implantdrug

The etonogestrel implant is an contraceptive implant that is placed into the upper arm.